Obagi Medical Products, Inc. (Obagi) is a specialty pharmaceutical company that develops, markets and sells, and is a provider of, topical aesthetic and therapeutic prescription-strength skin care systems and related products in the physician-dispensed market. Obagi systems and products are designed to prevent and improve the common and visible skin disorders in adult skin, including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, facial redness, and soft tissue deficits, such as fine lines and wrinkles. Obagi sells its products through a direct sales force in the United States and internationally through distribution partners in over 43 countries across North America, Central America, Europe, the Middle East and Asia. In April 2013, Valeant Pharmaceuticals International Inc acquired the entire share capital of Obagi Medical Products Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:OMPI
- CUSIP: N/A
- Web: N/A
- Trailing P/E Ratio:
- P/E Growth:
Frequently Asked Questions for Obagi Medical Products (NASDAQ:OMPI)
What is Obagi Medical Products' stock symbol?
Obagi Medical Products trades on the NASDAQ under the ticker symbol "OMPI."
Who are some of Obagi Medical Products' key competitors?
Some companies that are related to Obagi Medical Products include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Merck KGaA (MKGAY), Shire PLC (SHP), Zimmer Biomet Holdings (ZBH), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Health Net (HNT), Patheon NV (PTHN), NMC Health PLC (NMC), Catalent (CTLT), Cotiviti Holdings (COTV), Puma Biotechnology (PBYI) and Hikma Pharmaceuticals Plc (HIK).
How do I buy Obagi Medical Products stock?
Shares of Obagi Medical Products can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Obagi Medical Products' stock price today?
MarketBeat Community Rating for Obagi Medical Products (NASDAQ OMPI)MarketBeat's community ratings are surveys of what our community members think about Obagi Medical Products and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Obagi Medical Products stock can currently be purchased for approximately $23.98.
Consensus Ratings for Obagi Medical Products (NASDAQ:OMPI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Obagi Medical Products (NASDAQ:OMPI)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Obagi Medical Products (NASDAQ:OMPI)Earnings History by Quarter for Obagi Medical Products (NASDAQ OMPI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/14/2013||Q4 2012||$0.21||$0.15||$30.06 million||$30.30 million||View||Listen|
|11/1/2012||Q312||$0.20||$0.22||$28.87 million||$29.10 million||View||N/A|
Earnings Estimates for Obagi Medical Products (NASDAQ:OMPI)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Obagi Medical Products (NASDAQ:OMPI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Obagi Medical Products (NASDAQ:OMPI)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Obagi Medical Products (NASDAQ:OMPI)
Latest Headlines for Obagi Medical Products (NASDAQ:OMPI)
No headlines for this company have been tracked by MarketBeat.com
Obagi Medical Products (OMPI) Chart for Wednesday, July, 26, 2017